Metabolomic analysis reveals novel Isoniazid metabolites and hydrazones in human urine

Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 6, 2011, Pages 569-576

  Li, Feng ^a   Miao, Yan ^b   Zhang, Lirong ^c   Neuenswander, Sarah Ann ^d   Douglas, Justin T ^d   Ma, Xiaochao ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^b HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^c ZHENGZHOU UNIVERSITY   (China)

^d UNIVERSITY OF KANSAS   (United States)

Author keywords

Isoniazid; Mass spectrometry; Metabolism; Metabolomics; Nuclear magnetic resonance (NMR) spectrometry; Toxicity

Indexed keywords

2 OXO 1,2 DIHYDROPYRIDINE 4 CARBOHYDRAZIDE; DRUG METABOLITE; HYDRAZONE DERIVATIVE; ISOLEUCINE; ISONIAZID; ISONIAZID N OXIDE; LEUCINE; LYSINE; PHENYLALANINE; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; LIVER MICROSOME; MALE; METABOLOMICS; NORMAL HUMAN; POLYMERIZATION; SINGLE DRUG DOSE; URINALYSIS;

EID: 84855221918     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-RG-055     Document Type: Article

References (33)

1. Roux, A.: Isoniazid, a new chemotherapeutic agent isonicotinyl hydrazide. Prod. Pharm. Paris, 7: 493-495 1952.
2. Aita, J. F. and Calame, T. R.: Peripheral neuropathy secondary to isoniazid-induced pyridoxine deficiency. Md. State Med. J., 21: 68-70 1972.
3. Mahashur, A. A.: Isoniazid induced peripheral neuropathy. J. Assoc. Physicians India, 40: 651-652 1992.
4. Preziosi, P.: Isoniazid: metabolic aspects and toxicological correlates. Curr. Drug Metab., 8: 839-851 2007.
5. Timbrell, J. A., Mitchell, J. R., Snodgrass, W. R. and Nelson, S. D.: Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo. J. Pharmacol. Exp. Ther., 213: 364-369 1980.
6. Bahri, A. K., Chiang, C. S. and Timbrell, J. A.: Acetylhydrazine hepatotoxicity. Toxicol. Appl. Pharmacol., 60: 561-569 1981.
7. Mitchell, J. R., Thorgeirsson, U. P., Black, M., Timbrell, J. A., Snodgrass, W. R., Potter, W. Z., Jollow, H. R. and Keiser, H. R.: Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin. Pharmacol. Ther., 18: 70-79 1975.
8. Carlson, H. B., Anthony, E. M., Russell, W. F., Jr. and Middlebrook, G.: Prophylaxis of isoniazid neuropathy with pyridoxine. N. Engl. J. Med., 255: 119-122 1956.
9. Demiroglu, H. and Dundar, S.: Vitamin B6 responsive sideroblastic anaemia in a patient with tuberculosis. Br. J. Clin. Pract., 51: 51-52 1997.
10. Preziosi, P. and Porcellati, G.: Studies on the metabolism of isonicotinic hydrazide preliminary report. Boll. Soc. Ital. Biol. Sper., 29: 271-272 1953.
11. Hughes, H. B.: On the metabolic fate of isoniazid. J. Pharmacol. Exp. Ther., 109: 444-452 1953.
12. Johnson, W. J.: Biological acetylation of isoniazid. Nature, 174: 744-745 1954.
13. Makino, K., Kinoshita, T. and Itoh, T.: Biological acetylation of isonicotinyl hydrazide. Nature, 173: 36 1954.
14. Defranceschi, A. and Zamboni, V.: Identification of two metabolites of isoniazid {currency sign}isonicotinoylglycine and 1-isonicotinoyl-2-acetylhydrazine by paper chromatography in rat urine. Biochim. Biophys. Acta, 13: 304-305 1954.
15. Zamboni, V. and Defranceschi, A.: Identification of isonicotinoyl-hydrazones of pyruvic and alpha-ketoglutaric acid in rat urine after treatment with isonicotinic acid hydrazide isoniazid. Biochim. Biophys. Acta, 14: 430-432 1954.
16. Blair, I. A., Mansilla Tinoco, R., Brodie, M. J., Clare, R. A., Dollery, C. T., Timbrell, J. A. and Beever, I. A.: Plasma hydrazine concentrations in man after isoniazid and hydralazine administra-tion. Hum. Toxicol., 4: 195-202 1985.
17. Kaneo, Y., Kubo, H., Tabatam, T., Matsuyamam, K., Noda, A. and Iguchi, S.: Tissue distribution of isoniazid and its metabolites in rats. J. Pharmacobiodyn., 4: 590-595 1981.
18. McKennis, H., Jr., Yard, A. S., Weatherby, J. H. and Hagy, J. A.: Acetylation of hydrazine and the formation of 1,2-diacetylhydrazine in vivo. J. Pharmacol. Exp. Ther., 126: 109-116 1959.
19. Ellard, G. A., Gammon, P. T. and Wallace, S. M.: The determination of isoniazid and its metabolites acetylisoniazid, monoacetylhydrazine, diacetylhydrazine, isonicotinic acid and isonicotinylglycine in serum and urine. Biochem. J., 126: 449-458
20. Lindon, J. C. and Nicholson, J. K.: Spectroscopic and statistical techniques for information recovery in metabonomics and metabolomics. Annu. Rev. Anal. Chem. {currency sign}Palo Alto Calif, 1: 45-69 2008.
21. Cymerman Craig, J. and Purushothaman, K. K.: An improved preparation of tertiary amine N-oxides. J. Org. Chem., 35: 1721-1722 1970.
22. Hearn, M. J., Cynamon, M. H., Chen, M. F., Coppins, R., Davis, J., Joo-On Kang, H., Noble, A., Tu-Sekine, B., Terrot, M. S., Trombino, D., Thai, M., Webster, E. R. and Wilson, R.: Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid. Eur. J. Med. Chem., 44: 4169-4178 2009.
23. Chen, C., Meng, L., Ma, X., Krausz, K. W., Pommier, Y., Idle, J. R. and Gonzalez, F. J.: Urinary metabolite profiling reveals CYP1A2-mediated metabolism of NSC686288 aminoflavone. J. Pharmacol. Exp. Ther., 318: 1330-1342 2006.
24. Huang, Y. S., Chern, H. D., Su, W. J., Wu, J. C., Chang, S. C., Chiang, C. H., Chang, F. Y. and Lee, S. D.: Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology, 37: 924-930 2003.
25. Ohno, M., Yamaguchi, I., Yamamoto, I., Fukuda, T., Yokota, S., Maekura, R., Ito, M., Yamamoto, Y., Ogura, T., Maeda, K., Komuta, K., Igarashi, T. and Azuma, J.: Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int. J. Tuberc. Lung Dis., 4: 256-261 2000.
26. Kreis, B. and Boutonnet, G.: Increase in transaminases and jaundice during treatment with rifampicin combined with isoniazid«. Rev. Tuberc. Pneumol. Paris, 34: 1097-1106 1970.
27. Marche, J., Hugues, F. C., Graisely, B. and Marche, C.: Hepatitis induced by combination of rifampicin and isoniazid. Ann. Med. Interne {currency sign}Paris, 122: 1045-1054 1971.
28. Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T. and Kliewer, S. A.: The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest., 102: 1016-1023 1998.
29. Miguet, J. P., Mavier, P., Soussy, C. J. and Dhumeaux, D.: Induction of hepatic microsomal enzymes after brief administration of rifampicin in man. Gastroenterology, 72: 924-926 1977.
30. Vignati, L., Turlizzi, E., Monaci, S., Grossi, P., Kanter, R. and Monshouwer, M.: An in vitro approach to detect metabolite toxicity due to CYP3A4-dependent bioactivation of xenobiotics. Toxicology, 216: 154-167 2005.
31. Yoshikawa, Y., Hosomi, H., Fukami, T., Nakajima, M. and Yokoi, T.: Establishment of knockdown of superoxide dismutase 2 and expression of CYP3A4 cell system to evaluate drug-induced cytotoxicity. Toxicol. In Vitro, 23: 1179-1187 2009.
32. Whitehouse, L. W., Tryphonas, L., Paul, C. J., Solomonraj, G., Thomas, B. H. and Wong, L. T.: Isoniazid-induced hepatic steatosis in rabbits: an explanation for susceptibility and its antagonism by pyridoxine hydrochloride. Can. J. Physiol. Pharmacol., 61: 478-487 1983.
33. Hruskova, K., Kovarikova, P., Bendova, P., Haskova, P., Mackova, E., Stariat, J., Vavrova, A., Vavrova, K. and Simunek, T.: Synthesis and initial in vitro evaluations of novel antioxidant aroylhydrazone iron chelators with increased stability against plasma hydrolysis. Chem. Res. Toxicol., 24: 290-302 2011.